Brokerages Set $5.17 Price Target for Biota Pharmaceuticals Inc. (NASDAQ:AVIR)
Shares of Biota Pharmaceuticals Inc. (NASDAQ:AVIR) have been assigned an average broker rating score of 1.00 (Strong Buy) from the two brokers that cover the stock, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy recommendation.
Analysts have set a 12 month consensus target price of $5.17 for the company and are forecasting that the company will post ($0.30) EPS for the current quarter, according to Zacks. Zacks has also given Biota Pharmaceuticals an industry rank of 80 out of 265 based on the ratings given to its competitors.
Several research analysts recently commented on AVIR shares. FBR & Co restated an “outperform” rating on shares of Biota Pharmaceuticals in a report on Tuesday, May 31st. HC Wainwright began coverage on shares of Biota Pharmaceuticals in a research note on Wednesday, July 13th. They issued a “buy” rating and a $5.00 price target for the company.
Shares of Biota Pharmaceuticals (NASDAQ:AVIR) opened at 1.58 on Wednesday. The firm’s market capitalization is $61.05 million. Biota Pharmaceuticals has a 12 month low of $1.23 and a 12 month high of $2.31. The stock’s 50 day moving average is $1.36 and its 200 day moving average is $1.47.
Biota Pharmaceuticals (NASDAQ:AVIR) last announced its earnings results on Wednesday, September 14th. The company reported ($0.18) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.25 by $0.43. Biota Pharmaceuticals had a negative return on equity of 46.02% and a negative net margin of 272.04%. Equities research analysts forecast that Biota Pharmaceuticals will post ($0.89) earnings per share for the current fiscal year.
A number of hedge funds have recently made changes to their positions in AVIR. BVF Inc. IL purchased a new stake in shares of Biota Pharmaceuticals during the second quarter worth approximately $292,000. Eagle Global Advisors LLC bought a new position in shares of Biota Pharmaceuticals during the second quarter valued at $381,000. Bridgeway Capital Management Inc. bought a new position in shares of Biota Pharmaceuticals during the second quarter valued at $300,000. Senzar Asset Management LLC bought a new position in shares of Biota Pharmaceuticals during the second quarter valued at $2,848,000. Finally, FMR LLC bought a new position in shares of Biota Pharmaceuticals during the second quarter valued at $420,000. Hedge funds and other institutional investors own 34.53% of the company’s stock.
Biota Pharmaceuticals Company Profile
Aviragen Therapeutics, Inc, formerly Biota Pharmaceuticals Inc, is a biopharmaceutical company. The Company is focused on the discovery and development of direct-acting antivirals to treat infections. It has approximately four product candidates in clinical development that address viral infections that have limited therapeutic options.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Biota Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biota Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.